What the older studies reported
Older sermorelin studies reviewed on September 28, 2026 most often reported brief redness of the face and pain where the shot went in.
These findings came mainly from older studies in children, rather than long-term use of today’s compounded products in adults.
Read the review of the older studiesEvidence note
There is no current FDA-reviewed medicine information.
Sermorelin lacks a current FDA label as of September 28, 2026. A label is the official, agency-reviewed medicine information listing who must avoid a medicine and how often side effects happen.
Tell the person treating you about your health conditions and other medicines. Ask how these affect the plan and what is known for your case.
For pharmacy-made medicine, equivalent FDA-reviewed information on use during pregnancy or breastfeeding is unavailable.
If pregnancy plans or breastfeeding apply to you, ask about these too.
See the national label search used for this reviewWhat warnings about other drugs can tell you
In reviews of other drugs that trigger growth hormone release, the FDA warned that raised hormone levels could bring blood sugar problems, fluid build-up and tumour risks.
These warnings came from reviews of other drugs, not from studies counting how often these problems occurred in adults taking sermorelin.
Read the FDA discussion of related drugs- What parts of my history change the assessment?
- Which reactions need a message, which need a visit, and which require urgent help?
- Who would handle a problem between visits?